Kenneth Shain, MD, PhD provides an overview of recent advances in the treatment of relapsed and refractory multiple myeloma.
Back
Emerging Therapies in Relapsed or Refractory Multiple Myeloma
Kenneth Shain, MD, PhD reviews advances in treatment of relapsed and refractory multiple myeloma and data presented at 2021 International Myeloma Workshop.
Emerging Therapies in Relapsed or Refractory Multiple Myeloma
Episodes
All
All
Multiple myeloma expert Dr Kenneth Shain discusses mechanism of action of melphalan flufenamide and the advantage it might offer to fight cancer cells.
Kenneth Shain, MD, PhD reviews phase 3 OCEAN study design and safety and efficacy data from patients with RRMM treated with melphalan flufenamide + dexamethasone doublet or pomalidomide + dexamethasone.
Multiple myeloma expert Dr Kenneth Shain discusses the PORT study comparing central vs peripheral administration of melphalan flufenamide.
Dr Kenneth Shain, a multiple myeloma expert, discusses emerging therapies with newer mechanisms of action for patients with RRMM.
Kenneth Shain, MD, PhD discusses multiple myeloma disease measurement, management, and personalization of treatment going forward.
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 8/31/26
2
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
5